Article Type
Changed
Tue, 05/21/2019 - 12:18
Display Headline
Hereditary Cancer Risk Assessment in Obstetrics and Gynecology: The Evolving Standard of Care

The 2009 ACOG Practice Bulletin reported that “hereditary cancer risk assessment should be a part of routine Ob/Gyn practice.”1 As specialists in women’s health, this is our responsibility. Though it may be unfamiliar to many practitioners, the process of cancer risk stratification can be efficient and effective. Using protocol-driven evaluation of cancer susceptibility, personal and family risk factors, and genetic testing, we are now able to create risk profiles and management strategies that demonstrate proven reduction in cancer morbidity and mortality.

Sponsor
This supplement is sponsored by Myriad Genetics, Inc.
Article PDF
Author and Disclosure Information

 

Richard P. Frieder, MD, Medical Director, Cancer Genes Cancer Risk Assessment and Prevention Center of Santa Monica, Santa Monica, CA; Assistant Clinical Professor, Department of Obstetrics and Gynecology; David Geffen School of Medicine, UCLA, Los Angeles, CA.

Steven M. Berlin, MD, St. Joseph Medical Center, Towson, MD; Sinai Hospital, Baltimore, MD.

Dr. Frieder reports that he is a consultant and on the speakers' bureau for Myriad Genetics, Inc, and that he is a consultant for Phenogen Sciences, Inc; Perlegen Sciences, Inc; and Genetic Technologies Group.

Dr. Berlin reports that he is on the speakers' bureaus for Myriad Genetics, Inc and Qiagen.

Publications
Sections
Author and Disclosure Information

 

Richard P. Frieder, MD, Medical Director, Cancer Genes Cancer Risk Assessment and Prevention Center of Santa Monica, Santa Monica, CA; Assistant Clinical Professor, Department of Obstetrics and Gynecology; David Geffen School of Medicine, UCLA, Los Angeles, CA.

Steven M. Berlin, MD, St. Joseph Medical Center, Towson, MD; Sinai Hospital, Baltimore, MD.

Dr. Frieder reports that he is a consultant and on the speakers' bureau for Myriad Genetics, Inc, and that he is a consultant for Phenogen Sciences, Inc; Perlegen Sciences, Inc; and Genetic Technologies Group.

Dr. Berlin reports that he is on the speakers' bureaus for Myriad Genetics, Inc and Qiagen.

Author and Disclosure Information

 

Richard P. Frieder, MD, Medical Director, Cancer Genes Cancer Risk Assessment and Prevention Center of Santa Monica, Santa Monica, CA; Assistant Clinical Professor, Department of Obstetrics and Gynecology; David Geffen School of Medicine, UCLA, Los Angeles, CA.

Steven M. Berlin, MD, St. Joseph Medical Center, Towson, MD; Sinai Hospital, Baltimore, MD.

Dr. Frieder reports that he is a consultant and on the speakers' bureau for Myriad Genetics, Inc, and that he is a consultant for Phenogen Sciences, Inc; Perlegen Sciences, Inc; and Genetic Technologies Group.

Dr. Berlin reports that he is on the speakers' bureaus for Myriad Genetics, Inc and Qiagen.

Article PDF
Article PDF
Sponsor
This supplement is sponsored by Myriad Genetics, Inc.
Sponsor
This supplement is sponsored by Myriad Genetics, Inc.

The 2009 ACOG Practice Bulletin reported that “hereditary cancer risk assessment should be a part of routine Ob/Gyn practice.”1 As specialists in women’s health, this is our responsibility. Though it may be unfamiliar to many practitioners, the process of cancer risk stratification can be efficient and effective. Using protocol-driven evaluation of cancer susceptibility, personal and family risk factors, and genetic testing, we are now able to create risk profiles and management strategies that demonstrate proven reduction in cancer morbidity and mortality.

The 2009 ACOG Practice Bulletin reported that “hereditary cancer risk assessment should be a part of routine Ob/Gyn practice.”1 As specialists in women’s health, this is our responsibility. Though it may be unfamiliar to many practitioners, the process of cancer risk stratification can be efficient and effective. Using protocol-driven evaluation of cancer susceptibility, personal and family risk factors, and genetic testing, we are now able to create risk profiles and management strategies that demonstrate proven reduction in cancer morbidity and mortality.

Publications
Publications
Article Type
Display Headline
Hereditary Cancer Risk Assessment in Obstetrics and Gynecology: The Evolving Standard of Care
Display Headline
Hereditary Cancer Risk Assessment in Obstetrics and Gynecology: The Evolving Standard of Care
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media